Bionique Testing Laboratories and Cellipont Bioservices Form Rapid Mycoplasma Testing Partnership

• Bionique Testing Laboratories and Cellipont Bioservices have formed a strategic partnership to enhance rapid mycoplasma detection for cell and gene therapies.

• The agreement will support regulatory-aligned quality control (QC) and faster batch release for cGMP manufacturing.

Bionique Testing Laboratories, a provider of specialised mycoplasma testing services and part of the Asahi Kasei Group, has announced a collaboration with CDMO Cellipont Bioservices. The partnership aims to advance the adoption and validation of rapid mycoplasma detection methods to support cell and gene therapy manufacturing.

The collaboration will allow Cellipont to integrate validated rapid detection technologies into its QC processes, streamlining compliance and reducing batch release timelines. Bionique will supply tailored validation services and expertise to align with regulatory requirements.

“This partnership with Cellipont Bioservices represents an exciting opportunity for Bionique to support the advancement of cutting-edge cell therapies,” said Gladis Zamparo, CEO of Bionique Testing Laboratories.

Cellipont CEO Darren Head described Bionique as the “gold standard” in mycoplasma testing, citing the company’s collaborative approach and experience as key to strengthening QC strategies in a complex and evolving regulatory landscape.